Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Daily News

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

Yael L. Maxwell

January 27, 2022

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Conference News EAS 2018

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

Advertisement

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

OMT Boosts Survival in Revascularized Patients at 10 Years

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Recurrent Events Common Among Young Patients With CAD

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Quality of CAD Care Varies by Type of Medicare Coverage

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content